

TINIDAZOL — A NEW PREPARATION FOR *T. VAGINALIS* INFECTIONS

A LABORATORY AND CLINICAL EVALUATION

JOHN WALLIN

Department of Dermatology and Venorology, Uppsala University Hospital, Uppsala,
Sweden

The minimum trichomonocidal concentration of tinidazole for eight strains of *T. vaginalis* freshly isolated from patients were 1.25 to 2.5 µg/ml (mean 1.56). For metronidazole the values were 1.68 to 10 µg/ml (mean 3.83). Thus tinidazole had a trichomonocidal effect 1.3 to 8 times higher than that of metronidazole.

Moreover, 6 to 11 hrs after the ingestion of 2 g tinidazole in a single dose, the highest serum levels in four healthy volunteers were 20 to 40 µg/ml; 48 hrs after ingestion, the serum concentration of tinidazole remained higher than the minimum trichomonocidal concentration for most of the investigated strains of *T. vaginalis*.

Tinidazole was given in a single oral dose of 1.6 g to 64 women on an empty stomach, and in a single dose of 2 g to 51 women without food restrictions. Excluding re-infections, the overall recurrence rate was 6% and, in the group given 2 g tinidazole, 96% were cured. In three out of the six treatment failures, other concomitant genital disorders were present, but none had a genococcal infection at the time of treatment. Ten men were also treated and followed in the same way, with no observed failure.

The treatment was well tolerated in both groups. Five patients complained of gastric discomfort but none vomited. No abnormal white blood cells counts or transaminase values were caused by the drug.

Tinidazole given in a single oral dose therefore offers a potent and practicable way of treating *T. vaginalis* infections.

TINIDAZOL — NOWY PREPARAT PRZECIWRZĘSISTKOWY

OCENA LABORATORYJNA I KLINICZNA

J. WALLIN

Autor stosował Tinidazol doustnie w pojedynczej dawce 1,6 g u 64 kobiet i 2,0 g u 51 kobiet. Ogólny odsetek nawrotów — 6%. U leczonych dawką 2,0 g wyleczono 96% pacjentek. W ten sam sposób z wynikiem pomyślnym leczono także 10 mężczyzn. Najniższe rzęsistkobójcze stężenie Tinidazolu in vitro było 1,3-8,0 razy wyższe niż Metronidazolu (zależnie od szczepu *T. vaginalis*). Poza przejściowymi dolegliwościami żołądkowymi pięciorga leczonych, nie zanotowano żadnego innego ubocznego działania Tinidazolu.